Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

Amphastar Pharmaceuticals reported Q2 2025 net revenues of $174.4 million, a 4% year-over-year decrease, with GAAP net income falling to $31 million ($0.64/share) and adjusted net income to $40.9 million ($0.85/share), primarily due to increased competition in legacy products and the full commercialization costs of BAQSIMI impacting gross margin at 49.6%. Despite this, BAQSIMI sales surged 21% to $46.7 million, becoming a key revenue driver, and the company completed a $39.2 million share buyback while authorizing an additional $50 million program. Amphastar maintains its flat sales guidance for 2025, anticipating contributions from near-term FDA approvals of AMP-002 and AMP-015 (teriparatide), while strategically expanding U.S. manufacturing capacity and advancing its insulin aspart BLA (AMP-004) for long-term market potential, even as the GLP-1 ANDA market is expected to be crowded.

Analysis

Amphastar Pharmaceuticals' Q2 2025 results illustrate a strategic pivot, with strong performance from its acquired asset, BAQSIMI, offsetting significant competitive pressures on its legacy portfolio. While total revenue declined 4% year-over-year to $174.4 million and adjusted net income fell to $40.9 million, this was primarily driven by steep sales declines in injectable glucagon (-25%) and epinephrine (-42%) due to new market entrants and pricing erosion. The key positive highlight is BAQSIMI, whose sales grew 21% YoY to $46.7 million, validating its acquisition and establishing it as the company's primary growth driver. Gross margins contracted to 49.6% from 52.2%, a decline attributed to the normalization of BAQSIMI's cost accounting post-transition from Lilly and ongoing pricing headwinds. Management anticipates further margin contraction from legacy products, underscoring the critical importance of its pipeline. The company maintains its flat full-year revenue guidance, contingent on the risk-adjusted approvals of AMP-002 and AMP-015 this year. Strategically, Amphastar is investing for the long term by expanding its U.S. manufacturing capacity to de-risk its supply chain and support its pipeline, while a new $50 million share buyback signals confidence despite near-term challenges.

Key Decisions for Investors

• Investors should closely monitor FDA decisions for AMP-002 and AMP-015 before year-end, as the company's reaffirmed flat revenue guidance is highly dependent on the successful and timely launch of these two products.
• It is prudent to track the gross margin trajectory in the coming quarters, as profitability hinges on new, higher-margin products launching successfully to offset the guided, continued price and volume erosion in the legacy injectable glucagon portfolio.
• The sales momentum of BAQSIMI remains the most critical performance indicator, as its ability to sustain growth is essential for offsetting the competitive pressures that are impacting a significant portion of the company's legacy revenue base.
• Consider the strategic investment in quadrupling domestic manufacturing as a long-term de-risking of the supply chain that supports the company's shift towards more complex proprietary products like its insulin biosimilar, AMP-004.